Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Shengxue LuoInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.ORCID 0000-0001-7773-7092
Feifeng ZengInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Qitao DengDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
Yalin LuoInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Dawei ChenInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.ORCID 0000-0002-3405-6753
Hui RenInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Wenjie XiaInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Xin YeInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Shuxin HuangInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.ORCID 0000-0002-0634-4870
Tingting LiDepartment of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0001-5727-2179
Yongshui FuInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Xia RongInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.ORCID 0000-0002-2463-6340
Huaqin LiangInstitute of Blood Transfusion and Hematology, Guangzhou Blood Center, Guangzhou Medical University, Guangzhou 510095, China.
Funding
"Cell Engineering Joint Laboratory of University-Blood Center-Enterprise" of Guangdong undergraduate university teaching quality and teaching reform project 2024The Key Medical Disciplines and Specialties Program of Guangzhou 2025-2027The National Natural Science Foundation of China 32471001, and 82302001the Science and Technology Projects in Guangzhou 2024A03J0079, 2025A03J3369, 2025A03J3367, and 2025A04J3392
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
anti-CD137anti-CD16anti-tumor efficacyperipheral blood mononuclear cellssuper NK cells
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Antibody-Mediated In Vitro Activation and Expansion of Blood Donor-Derived Natural Killer Cells with Transient Anti-Tumor Efficacy. · full record | OpenQuestion